Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-63978-y
Affiliations:
5
Authors:
12
Go to article
Institutions Authors Share
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China
11.000000
11.000000
 0.92
Sichuan University (SCU), China
1.000000
 0.08
Interested in Oncology and Carcinogenesis?